Welcome to our dedicated page for NOVONIX SEC filings (Ticker: NVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NOVONIX Limited filings document foreign-issuer reporting for an ADR-listed battery materials and technology company. Its Form 6-K reports furnish ASX announcements, operating and financial results, material-event disclosures, material agreements, shareholder voting matters, and governance updates.
Company filings also record capital-structure activity such as applications for quotation of ordinary fully paid shares, notifications of unquoted equity securities, employee incentive performance rights, and director interest notices. These disclosures connect NOVONIX's public reporting with its ordinary shares, American depositary shares, incentive securities, and governance obligations as an Australian issuer with U.S. reporting.
NOVONIX Limited has launched a Share Purchase Plan (SPP) giving eligible Australian and New Zealand shareholders the option to buy additional shares at a discounted price. The company aims to raise about A$3.0 million through the SPP at an issue price of A$0.16 per share.
Each eligible holder can apply for parcels of up to A$30,000 in new shares without brokerage, with pricing set at a 33.3% discount to the A$0.24 closing price on 15 June 2026 and a 31.2% discount to the five‑day VWAP to that date. The SPP follows an institutional placement that raised approximately A$20.7 million, with combined proceeds earmarked for capital expenditure to expand production capacity and meet forecast customer demand.
Novonix Limited has applied to quote 129,334,163 new ordinary fully paid shares on the ASX. These shares were issued as part of a previously announced placement and are priced at AUD 0.16 per share, with an issue date of June 22, 2026.
After quotation, Novonix will have 991,561,920 ordinary shares on issue. The company also has unquoted instruments on issue, including 27,401,382 performance rights, 14,016,667 options, 1,371,566 share rights, 45,221,586 convertible notes and 35,000,000 convertible debentures, which together outline additional potential equity overhang.
NOVONIX Limited is raising new equity through an institutional placement and a discounted share purchase plan. The company received firm commitments for approximately A$20.7 million via an Institutional Placement of 129,334,163 fully paid ordinary shares at A$0.16 per share, using its remaining 15% placement capacity under ASX Listing Rule 7.1.
In parallel, NOVONIX is launching a Share Purchase Plan (SPP) allowing eligible Australia and New Zealand shareholders to apply for up to A$30,000 of shares each, at the same A$0.16 offer price, with a maximum of 18,750,000 SPP shares and an expected raise of approximately A$3.0 million if fully subscribed.
The offer price represents a 33.3% discount to the last traded price of A$0.24 on 15 June 2026 and a 31.2% discount to the five-day VWAP of A$0.23. Proceeds are expected to fund capital expenditure to expand production capacity and support forecast customer demand. A trading halt was requested on 16 June 2026 ahead of the capital raising announcement.
NOVONIX Limited reported a key operational milestone, delivering a mass production qualification “C-sample” of synthetic graphite anode active material to its lead customer, Panasonic Energy. The company says internal testing shows the material meets Panasonic’s required specifications, while formal validation will depend on Panasonic’s assessment in the coming months.
The delivery is described as the first known Synthetic Graphite AAM C-sample produced in North America and is framed as an important step toward a secure U.S. battery materials supply chain. NOVONIX also reaffirmed its expectation that mass production for Panasonic will begin in the second half of 2027, subject to successful completion of qualification by Panasonic and its customers.
NOVONIX Limited reports a leadership transition in its finance team. Chief Financial Officer Robert Long will leave the company in July to pursue other opportunities. Current Chair Ron Edmonds, a veteran finance leader formerly with Dow Chemical, will serve as Interim Chief Financial Officer and step aside as Chair during the search for a permanent replacement. Deputy Chair Admiral Robert Natter will take over as Chair so Edmonds can focus on the interim CFO role. The Board states it is confident these arrangements will maintain leadership continuity and support ongoing operations while a new full-time CFO is recruited.
NOVONIX Ltd Chief Operating Officer Dwayne Arnold Johnson reported six Form 4 transactions involving performance rights linked to ordinary shares. All are coded as “other acquisition or disposition” (code J) and classified as restructuring transactions covering an aggregate 2,932,881 performance rights at an exercise price of $0.0000 per right. No shares were reported as bought or sold, and the transaction summary shows zero net buy or sell activity.
NOVONIX LIMITED reported that 2,932,881 unquoted NVXAD performance rights have lapsed because the performance conditions were not met or can no longer be satisfied. No consideration was paid for this cessation.
After this change, the company has 862,227,757 ordinary fully paid shares on issue, alongside remaining unquoted performance rights, options, share rights and convertible notes.
NOVONIX Limited has applied to quote 784,817 new ordinary fully paid shares on the ASX, issued on 13 May 2026 after the conversion of performance rights under an employee incentive scheme. These additional shares form part of the existing NVX ordinary share class and rank equally with existing shares.
The shares are being issued for non‑cash consideration, with an estimated value of AUD 0.235 per security. After this quotation, the company reports a total of 862,227,757 NVX ordinary fully paid shares on issue, alongside several classes of unquoted performance rights, options, share rights, convertible notes and convertible debentures.
NOVONIX Ltd director Robert J. Natter reported internal transfers of company shares between accounts he beneficially owns. On the reported date, three “J” code transactions moved a total of 460,686 ordinary shares among direct holdings and family trusts at a stated price of $0.0000 per share.
A footnote explains these were administrative transfers and did not change his overall economic interest in NOVONIX securities. He also holds share rights over 195,938 underlying ordinary shares with a stated exercise price of $0.0000 and an expiration date of December 31, 2027.
NOVONIX Ltd director Tony Bellas reported his derivative holdings of share rights linked to ordinary shares. The filing shows 195,938 underlying ordinary shares tied to these share rights at an exercise price of $0.0000 per share, exercisable from December 31, 2026 and expiring on December 31, 2027. No purchases or sales were reported; this entry updates his position in these rights.